The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family
Open Access
- 15 June 2016
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (6) , 909
Abstract
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. RET/PTC rearrangement is the most common genetic modification identified in this category of cancer, increasing proliferation and dedifferentiation by the activation of the RET/PTC-RAS-BRAF-MAPK-ERK signaling pathway. Recently, let-7 miRNA was found to reduce RAS levels, acting as a tumor suppressor gene. Circulating miRNA profiles of the let-7 family may be used as novel noninvasive diagnostic, prognostic, treatment and surveillance markers for PTC.Keywords
Funding Information
- Medical University of Lodz (503/0-079-02/503-01-001)
This publication has 35 references indexed in Scilit:
- Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated withBRAFMutation and Clinicopathological Features in Chinese PatientsInternational Journal of Endocrinology, 2013
- Regulation of let-7 and its target oncogenes (Review)Oncology Letters, 2012
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular originThyroid Research, 2011
- MicroRNA Role in Thyroid Cancer DevelopmentJournal of Thyroid Research, 2011
- Thyroid Cancer: Current Molecular PerspectivesJournal of Oncology, 2010
- Analysis of Deregulated miRNAs is Helpful to Distinguish Poorly Differentiated Thyroid Carcinoma from Papillary Thyroid CarcinomaHormone and Metabolic Research, 2009
- Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumorsRNA, 2007
- MicroRNAs in human cancer: from research to therapyJournal of Cell Science, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006